ArticleScientific reports2025
Comparative cohort study of pregabalin nortriptyline and pregabalin duloxetine in the management of diabetic peripheral neuropathic pain.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic Peripheral Neuropathic Pain (DPNP) is a chronic complication affecting nearly half of individuals with diabetes. While monotherapies like pregabalin, duloxetine, and nortriptyline are frequently used, combination regimens may offer enhanced efficacy. Comparative studies of pregabalin-nortriptyline (PG-NT) and pregabalin-duloxetine (PG-DLX), especially in Indian populations, remain limited. A retrospective-prospective cohort study was conducted over five months at a tertiary care centre in South India. Sixty adults with DPNP, treated for at least two months with PG-NT or PG-DLX, were followed for nine weeks. Participants received either pregabalin-nortriptyline (dosed 150-300 mg/day and 10-75 mg/day, respectively) or pregabalin 150-300 mg/day with duloxetine 60 mg/day, for nine weeks. Efficacy was assessed using the Visual Analogue Scale (VAS), Insomnia Severity Index (ISI), and Hospital Anxiety and Depression Scale (HADS). Adverse events were documented. Both regimens significantly reduced pain scores. PG-DLX showed greater reductions in VAS (-2.23 vs. -1.35), ISI (-2.87 vs. -1.14), and HADS-A (-2.00 vs. -1.41). PG-DLX also significantly improved HADS-D scores (-1.70; p < 0.001), while PG-NT did not (p = 0.076). Adverse events were mild but more frequent with PG-DLX (30% vs. 16.67%). Both combinations are effective for managing DPNP. However, PG-DLX demonstrated superior benefits in pain relief, sleep quality, and mood symptoms, with a modest increase in mild adverse events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.